BLINCYTO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLINCYTO (BLINCYTO).
Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.
| Metabolism | Metabolized to small peptides by catabolic pathways; not metabolized by CYP enzymes. |
| Excretion | Blinatumomab is not metabolized by cytochrome P450 enzymes; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion studies have been conducted; however, clearance is primarily through non-specific proteolysis, and no significant renal or biliary excretion of intact drug occurs. The contribution of renal elimination to total clearance is minimal (<1%). |
| Half-life | The terminal elimination half-life of blinatumomab is approximately 2.11 hours (range 1.2–2.5 hours) during continuous intravenous infusion. The short half-life necessitates continuous infusion to maintain therapeutic concentrations. |
| Protein binding | Blinatumomab is a monoclonal antibody; protein binding is negligible at clinically relevant concentrations. No specific binding to plasma proteins has been reported. |
| Volume of Distribution | The volume of distribution (Vd) at steady state is approximately 3.13 L (range 2.35–4.38 L), corresponding to about 0.04 L/kg (assuming 70 kg body weight), suggesting limited extravascular distribution consistent with a large monoclonal antibody. |
| Bioavailability | Blinatumomab is administered as a continuous intravenous infusion; bioavailability by this route is 100%. No other routes are clinically relevant. |
| Onset of Action | Clinical response (e.g., reduction in bone marrow blasts) can be observed within 2 to 4 weeks after initiation of continuous intravenous infusion at the recommended dosing regimen. |
| Duration of Action | The duration of action is dependent on continuous infusion; pharmacodynamic effects (e.g., T-cell activation and cytokine release) persist for the duration of the infusion. After infusion discontinuation, drug concentrations decline rapidly due to short half-life, and clinical effects wane accordingly. |
Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min) or dialysis, use with caution and monitor for increased toxicity; specific dose adjustments not established. |
| Liver impairment | No dedicated Child-Pugh based adjustments available. Use with caution in patients with moderate to severe hepatic impairment; monitor for hepatotoxicity. |
| Pediatric use | For patients weighing ≥45 kg: same as adult dosing. For patients <45 kg: based on body surface area (BSA). Cycle 1: 5 mcg/m2/day (max 9 mcg/day) on days 1-7, then 15 mcg/m2/day (max 28 mcg/day) on days 8-28. Subsequent cycles: 15 mcg/m2/day (max 28 mcg/day) on days 1-28. Administer as continuous IV infusion over 28 days. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BLINCYTO (BLINCYTO).
| Breastfeeding | There are no data on blinatumomab presence in human milk, effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions from a large IgG protein, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose. |
| Teratogenic Risk | Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. IgG molecules cross the placenta, with increasing transfer in the second and third trimesters. Limited human data exist; however, it is expected to pose a risk of fetal B-cell lymphopenia, immunomodulation, and potential teratogenicity. Use during pregnancy should be avoided unless the benefit clearly outweighs the risk. |
■ FDA Black Box Warning
Cytokine release syndrome (CRS), which may be life-threatening or fatal; neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or fatal.
| Serious Effects |
Known hypersensitivity to blinatumomab or any component of the formulation.
| Precautions | Cytokine release syndrome, neurological toxicities (including ICANS), infections, neutropenia and febrile neutropenia, tumor lysis syndrome, leukopenia, increased liver enzymes, pancreatitis, preparation and administration errors, and embryo-fetal toxicity. |
| Food/Dietary | No clinically significant food interactions reported. Grapefruit and grapefruit juice do not affect blinatumomab as it is a monoclonal antibody not metabolized by CYP450 enzymes. No dietary restrictions required. |
Loading safety data…
| No specific dose adjustment recommended for elderly patients. Monitor closely for adverse reactions, particularly neurologic events and infections, as clinical studies included limited patients aged ≥65 years. |
| Fetal Monitoring | For pregnant women receiving blinatumomab, monitor for signs of cytokine release syndrome (CRS), neurological toxicities, and infections. Fetal monitoring should include ultrasonography to assess growth and development, and consider fetal echocardiography if maternal cardiac toxicity occurs. |
| Fertility Effects | No formal human studies on fertility. Animal studies have not been conducted to evaluate effects on fertility. Based on mechanism, potential for impairment of male and female fertility due to effects on immune function and possible gonadal toxicity, but specific data are lacking. |
| Clinical Pearls | Premedicate with corticosteroids (e.g., dexamethasone 20 mg IV) 1 hour before infusion to reduce the risk of cytokine release syndrome (CRS). Monitor for neurological toxicities, including seizures and encephalopathy, especially during the first 2 doses. Dose adjustments are required for patients with renal impairment (CrCl < 30 mL/min). Blinatumomab is administered as a continuous IV infusion over 28 days per cycle; do not flush the line to prevent bolus administration. |
| Patient Advice | This medication is given as a continuous infusion through a vein over 28 days; you will have a portable infusion pump. · Common side effects include fever, chills, headache, and nausea; these are often manageable with medications. · Seek immediate medical attention if you experience severe headache, confusion, seizures, difficulty speaking, or vision changes (signs of neurological toxicity). · Report any signs of infection such as fever, chills, or sore throat; blinatumomab can lower your white blood cell count. · Do not disconnect, adjust, or stop the infusion pump without consulting your healthcare provider. |